Title: Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are
effective in the treatment of colorectal cancer
Version: 1 Date: 28 Sep 2023
Reviewer's report:
Authors propose in this manuscript the application of CAR-T cells targeting EpCAM as
treatment for colorectal cancer. CAR-T cell therapy have demonstrated to be effective in treating
hematological malignancies and its investigations have leaded to its application in solid tumors.
EpCAM has already been investigated as a potential target for treating solid tumors with
encouraging results. In this manuscript they also conclude that EpCAM-CAR-T cells can inhibit
tumor growth. The manuscript would be improved by consideration of the following points:
- Section 2.1 there is no information about where tumor cells come from and how they achieved
EpCAM expression in tumor cells. I also found missing the dose and route of CAR-T cells
treatment that have been infused into mice.
- In CAR-T cells production, I found missing T cell activation and expansion.
- Why did the authors use 4 cell lines (HEK293T, HT-29, HCT116 and Hela)? In results section
3.3 why authors just use HT-29 and Hela?.
- Section 3.4. Figures referenced does not match with the images.
- In discussion, justify why the tumoricidal effect is due to the increase in TNF and INF and
not to direct tumor destruction by CAR-T cells, and that the increase in TNF is merely an effect
of lymphocyte activation.
- Please discuss why tumor section showed no significant lymphocyte infiltration and how can
CAR-T cells can have an antitumor effect if no cells are detected in the tumor.
- In figure 5 description, it indicates that tumors were formed by subcutaneous implantation,
however, in methods appears as intraperitoneal injection. Please clarify this.
Title: Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are
effective in the treatment of colorectal cancer
Version: 1 Date: 28 Sep 2023
Reviewer's report:
Authors propose in this manuscript the application of CAR-T cells targeting EpCAM as
treatment for colorectal cancer. CAR-T cell therapy have demonstrated to be effective in treating
hematological malignancies and its investigations have leaded to its application in solid tumors.
EpCAM has already been investigated as a potential target for treating solid tumors with
encouraging results. In this manuscript they also conclude that EpCAM-CAR-T cells can inhibit
tumor growth. The manuscript would be improved by consideration of the following points:
- Section 2.1 there is no information about where tumor cells come from and how they achieved
EpCAM expression in tumor cells. I also found missing the dose and route of CAR-T cells
treatment that have been infused into mice.
- In CAR-T cells production, I found missing T cell activation and expansion.
- Why did the authors use 4 cell lines (HEK293T, HT-29, HCT116 and Hela)? In results section
3.3 why authors just use HT-29 and Hela?.
- Section 3.4. Figures referenced does not match with the images.
- In discussion, justify why the tumoricidal effect is due to the increase in TNF and INF and
not to direct tumor destruction by CAR-T cells, and that the increase in TNF is merely an effect
of lymphocyte activation.
- Please discuss why tumor section showed no significant lymphocyte infiltration and how can
CAR-T cells can have an antitumor effect if no cells are detected in the tumor.
- In figure 5 description, it indicates that tumors were formed by subcutaneous implantation,
however, in methods appears as intraperitoneal injection. Please clarify this.
Please review this paper.
user
Title: Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are
effective in the treatment of colorectal cancer
Version: 1 Date: 28 Sep 2023
Reviewer's report:
Authors propose in this manuscript the application of CAR-T cells targeting EpCAM as
treatment for colorectal cancer. CAR-T cell therapy have demonstrated to be effective in treating
hematological malignancies and its investigations have leaded to its application in solid tumors.
EpCAM has already been investigated as a potential target for treating solid tumors with
encouraging results. In this manuscript they also conclude that EpCAM-CAR-T cells can inhibit
tumor growth. The manuscript would be improved by consideration of the following points:
- Section 2.1 there is no information about where tumor cells come from and how they achieved
EpCAM expression in tumor cells. I also found missing the dose and route of CAR-T cells
treatment that have been infused into mice.
- In CAR-T cells production, I found missing T cell activation and expansion.
- Why did the authors use 4 cell lines (HEK293T, HT-29, HCT116 and Hela)? In results section
3.3 why authors just use HT-29 and Hela?.
- Section 3.4. Figures referenced does not match with the images.
- In discussion, justify why the tumoricidal effect is due to the increase in TNF and INF and
not to direct tumor destruction by CAR-T cells, and that the increase in TNF is merely an effect
of lymphocyte activation.
- Please discuss why tumor section showed no significant lymphocyte infiltration and how can
CAR-T cells can have an antitumor effect if no cells are detected in the tumor.
- In figure 5 description, it indicates that tumors were formed by subcutaneous implantation,
however, in methods appears as intraperitoneal injection. Please clarify this.
assistant